LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Начало・Списък с акции・Novocure Ltd

Novocure Ltd

Затворен

СекторЗдравеопазване

10.91 -3.37

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.87

Максимум

11.04

Ключови измерители
By Trading Economics
Приходи	2.9M -37M
Продажби	8.4M 167M
EPS	-0.33
Марж на печалбата	-22.29
Служители	1,488
EBITDA	9.7M -26M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+160.07% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-149M 1.4B
Предишно отваряне	14.28
Предишно затваряне	10.91

Настроения в новините

By Acuity

100%

361 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

16.31 / 18.14 Подкрепа & съпротива

Novocure Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.11.2025 г., 21:06 ч. UTC

Значими двигатели на пазара

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8.11.2025 г., 18:10 ч. UTC

Печалби

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8.11.2025 г., 13:10 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8.11.2025 г., 12:00 ч. UTC

Печалби

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8.11.2025 г., 10:30 ч. UTC

Печалби

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8.11.2025 г., 03:50 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8.11.2025 г., 03:41 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8.11.2025 г., 03:07 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 20:59 ч. UTC

Печалби

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7.11.2025 г., 20:26 ч. UTC

Пазарно говорене

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7.11.2025 г., 20:22 ч. UTC

Печалби

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7.11.2025 г., 20:04 ч. UTC

Пазарно говорене

Oil Futures Close Choppy Week With Losses -- Market Talk

7.11.2025 г., 19:34 ч. UTC

Пазарно говорене

Gold Posts Small Gain for Week -- Market Talk

7.11.2025 г., 19:31 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7.11.2025 г., 19:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7.11.2025 г., 19:09 ч. UTC

Печалби

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7.11.2025 г., 19:08 ч. UTC

Печалби

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7.11.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7.11.2025 г., 17:27 ч. UTC

Пазарно говорене

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Novocure Ltd Прогноза

Ценова цел

By TipRanks

160.07% нагоре

12-месечна прогноза

Среден 28.4 USD 160.07%

Висок 42 USD

Нисък 18 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Novocure Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Novocure Ltd през последните 3 месеца.

Техническа оценка

By Trading Central

16.31 / 18.14Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.